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Abstract
Background:  To analyse available evidence on the efficacy and safety of anti-TNFα drugs
(infliximab, etanercept and adalimumab) for treating rheumatoid arthritis (RA).
Methods: We searched systematically for randomised controlled clinical trials on treatment of RA
with anti-TNFα drugs, followed by a systematic review with metaanalysis. Trials were searched
from MEDLINE, EMBASE and Cochrane Library databases. The American College of Rheumatology
(ACR) efficacy response criteria were used. Safety parameters provided by the trials were also
assessed. Positive and undesired effects were estimated using combined relative risks (RR), number
needed to treat (NNT) and number needed to harm (NNH). Heterogeneity was evaluated by
Cochrane's Q and I2 statistics.
Results: Thirteen trials (7087 patients) met the inclusion criteria. The combined RR to achieve a
therapeutic response to treatment with recommended doses of any anti-TNFα drug was 1.81 (95%
CI 1.43–2.29) with a NNT of 5 (5–6) for ACR20. NNT for ACR50 [5 (5–6)] and ACR70 [7 (7–9)]
were similar. Overall therapeutic effects were also similar regardless of the specific anti-TNFα drug
used and when higher than recommended doses were administered. However, lower than
recommended doses elicited low ACR70 responses (NNT 15). Comparison of anti-TNFα drugs
plus methotrexate (MTX) with MTX alone in patients with insufficient prior responses to MTX
showed NNT values of 3 for ACR20, 4 for ACR50 and 8 for ACR70. Comparison of anti-TNFα
drugs with placebo showed a similar pattern. Comparisons of anti-TNFα drugs plus MTX with
MTX alone in patients with no previous resistance to MTX showed somewhat lower effects.
Etanercept and adalimumab administered as monotherapy showed effects similar to those of MTX.
Side effects were more common among patients receiving anti-TNFα drugs than controls (overall
combined NNH 27). Patients receiving infliximab were more likely to drop out because of side
effects (NNH 24) and to suffer severe side effects (NNH 31), infections (NNH 10) and infusion
reactions (NNH 9). Patients receiving adalimumab were also more likely to drop out because of
side effects (NNH 47) and to suffer injection site reactions (NNH 22). Patients receiving etanercept
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were less likely to drop out because of side effects (NNH for control versus etanercept 26) but
more likely to experience injection site reactions (NNH 5).
Conclusion:  Anti-TNFα drugs are effective in RA patients, with apparently similar results
irrespective of the drug administered. Doses other than those recommended are also beneficial.
The main factor influencing therapeutic efficacy is the prior response to DMARD treatment. The
effect of treatment with etanercept or adalimumab does not differ from that obtained with MTX.
The published safety profile for etanercept is superior but the fact that no patients are treated with
higher than recommended doses requires explanation.
Background
Rheumatoid arthritis (RA) is a chronic, systemic, inflam-
matory disease of the joints, which often causes joint
destruction, deformity and functional impairment [1].
Early administration of disease-modifying antirheumatic
drugs (DMARDs) is crucial and the use of nonsteroidal
anti-inflammatory drugs and glucocorticoids remains a
fundamental aspect of medical management of RA. The
discovery that the macrophage-derived proinflammatory
cytokine tumour necrosis factor alpha (TNFα) plays a cen-
tral role in the pathogenesis of RA [2] led to the introduc-
tion of anti-TNFα drugs, a new biological DMARD class.
Evidence showing that anti-TNFα drugs are very effective
in RA has led to a substantial change in the treatment of
this disease [3]. Three such drugs have been commercial-
ized since 1999: infliximab, etanercept and adalimumab.
Despite this relative short history, a considerable amount
of information has already been accumulated [4-6]. How-
ever, many questions about this new class of drugs still
remain unanswered: are all available anti-TNFα drugs
equally effective; does their efficacy depend upon their
being administered together with methotrexate (MTX);
does efficacy depend on dose; are they more effective than
MTX; are all anti-TNFα drugs equally safe; what is the effi-
cacy/safety profile? To date, no direct "head-to-head"
comparative studies of the different anti-TNFα drugs have
been published. An alternative approach to answering the
foregoing questions is to perform a systematic review with
metaanalysis of relevant research. A metaanalysis with
emphasis on the risk of cancer and infections has been
reported [7]. Also, a study using an indirect comparative
approach to the relative efficacies of the three anti-TNFα
drugs in the treatment of RA showed no differences
among them [8].
In this paper, we conduct a systematic review of ran-
domised controlled clinical trials of anti-TNFα drugs in
RA followed by a metaanalysis of the efficacy and safety of
different doses of infliximab, etanercept and adalimu-
mab.
Methods
Study selection criteria
We carried out a search of all randomised controlled clin-
ical trials of anti-TNFα drugs (infliximab, etanercept or
adalimumab) for treating patients with RA. Patients had
to satisfy the American College of Rheumatology (ACR)
criteria [9] for diagnosis and to have active disease. Trial
duration had to be at least 6 months with efficacy meas-
ured by ACR response [10]. Clinical trials were excluded if
they either used administration routes other than recom-
mended or included no treatment arm with recom-
mended doses. Only information published in the trial
reports was assessed.
Efficacy parameters
We used the ACR responses ACR20, ACR50 and ACR70
(improvements of at least 20, 50 and 70%, respectively,
on a series of predetermined measures) as efficacy param-
eters [10].
Safety parameters
The following safety parameters reported in the selected
trials were analyzed: number of patients suffering any
adverse event, withdrawals due to adverse events, serious
adverse events, infections, serious infections, infusion
reactions, injection-site reactions, malignancies and over-
all mortality.
Search strategy
Trials were searched in scientific journals and congress
conference proceedings. Information from the MEDLINE,
EMBASE and Cochrane Library databases up to October
2006 was checked using a high-sensitivity strategy. The
descriptors used were rheumatoid arthritis, infliximab,
etanercept, adalimumab, randomised controlled trial and
meta-analysis. The computerised search was completed
with a manual search of reference lists from the articles
retrieved and from rheumatological journal articles pub-
lished in 2006 (technical details are available from the
authors). There was no language restriction.
Data extraction
Two investigators (AA-R and MC) independently exam-
ined each eligible study and extracted data. Trials withBMC Musculoskeletal Disorders 2008, 9:52 http://www.biomedcentral.com/1471-2474/9/52
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information only in abstract format were excluded. Data
were extracted using an ad hoc form with key items for
each trial: study design, patients' characteristics (sex, age
and duration of disease evolution), patient inclusion cri-
teria, drugs and doses used, treatment duration and ACR
response and safety parameters. Special attention was
paid to both inclusion criteria and clinical features of
patients included in each trial, as they were deemed cen-
tral aspects for assessing heterogeneity. The quality of each
individual study was assessed and scored using the Jadad
scale [11].
Statistical analysis
For each single trial the relative risk (RR) of attaining an
ACR response was obtained as a measure of the effect.
Overall efficacy estimates (combined relative risk) for
each anti-TNFα drug (as monotherapy or in association
with MTX or another DMARD) compared to a control
(placebo, MTX or another DMARD) were attained using
the ACR20, ACR50, and ACR70 criteria as the main out-
come variables. We used DerSimonian-Laird's method to
estimate a random-effects model. Heterogeneity was eval-
uated using Cochrane's Q and I2 statistics and explored via
subgroup analysis. The I2 statistic is calculated from Q and
can be interpreted as the percentage variability in study
results attributable to between-study differences [12]. The
number of patients needed for experimental treatment
versus control (NNT) to obtain an additional positive
ACR response was also estimated [13].
We also used the RR to estimate the risk of adverse effects;
and we estimated the number needed to harm (NNH),
defined as the number of patients receiving active treat-
ment that would harm one patient compared to controls
[13-15].
Publication bias was assessed graphically using a funnel
plot [16] and statistically evaluated by the regression sym-
metry test described by Egger et al. [17] and the adjusted
rank correlation test proposed by Begg and Mazumdar
[18]. We used the specific software Comprehensive
Metaanalysis Version 2.0 for analysis and presentation of
main results.
Results
Search results
Of the 46 publications located [19-65], only 15 met the
selection criteria and were consequently included in the
metaanalysis [19-33]. The remaining 31 were excluded for
several reasons [34-64] (Figure 1). The Maini trial [21]
was included in the Lipsky et al. trial [19] and the van der
Heijde et al. [28] and Klareskog et al. [27] trials were the
same (TEMPO trial). We analyzed the entire set of 7087
patients recruited for the 13 trials selected: four using inf-
liximab [19,20,22,23] (2581 patients), four etanercept
[24-26,28] (1637 patients) and five adalimumab [29-33]
(2869 patients). The methodological quality of the stud-
ies was moderate to high (3–5) except Bathon's trial [24],
which had a lower Jadad score of 2 because it neither men-
tioned nor explained whether treatment allocation was
based on a random procedure (Table 1).
Trial characteristics
Table 1 shows the major characteristic of the 13 trials
included in the review. Information on efficacy at 6, 12
and 24 months and the previously-described safety
parameters were analyzed.
There are four infliximab trials: Lipsky et al. [19], St. Clair
et al. [20], Quinn et al. [22] and Westhovens et al. [23].
Lipsky et al. [19] used a randomised double blind 12-
month trial (with information at 6 and 12 months). Four
hundred and twenty-eight patients insufficiently respon-
sive to MTX were included. Patients were randomized to 5
arms, four with infliximab plus MTX and a control arm
with MTX alone. The purpose of this study was to demon-
strate that infliximab was capable of inhibiting the pro-
gression of structural joint damage. It was a continuation
of the Maini et al. trial [21]. The St. Clair et al. trial [20]
compared infliximab plus MTX with MTX alone. The 1049
patients included in this trial had a recent onset of RA
(disease duration in the range 3 months to 3 years). They
had not previously received MTX, and MTX was adminis-
tered following a rapid dose-increasing schedule during
the trial (7.5 mg/wk at week 0, increasing by 2.5 mg per
week to 15 mg/wk at week 5 and 20 mg/wk at week 8).
The trial lasted 12 months. The Quinn et al. [22] trial was
a small study comparing infliximab plus MTX with MTX
alone in recent-onset RA patients. Westhovens et al. [23]
conducted a 12-month trial but the double blind efficacy
data were analyzed at week 22.
Four trials testing etanercept were analysed. Moreland et
al. [24] compared etanercept in monotherapy with a pla-
cebo. Weinblatt et al. [25] compared etanercept plus MTX
with MTX alone. In the Bathon et al. trial [26], etanercept
in monotherapy was compared with MTX. Finally, the
TEMPO trial (Trial of Etanercept and Methotrexate with
radiographic Patient Outcomes) [28] compared etaner-
cept in monotherapy with both MTX and a combination
of etanercept plus MTX. Moreland et al. included 234
patients [24] in a 6 month-trial comparing the response to
etanercept with placebo. Patients had previously shown
an inadequate response to at least 1 DMARD (80% to
MTX). They had received an average of three DMARDs
and were therefore defined as refractory to standard treat-
ments. Weinblatt et al. [25] included 89 patients with
inadequate responses to MTX. The duration of the trial
was 6 months. Bathon et al. [26] recruited 632 patients
with recent RA onset (less than 3 years' duration). PatientsBMC Musculoskeletal Disorders 2008, 9:52 http://www.biomedcentral.com/1471-2474/9/52
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Flow chart of the selection process for inclusion of Randomised Controlled Trials (RCT) in the overview Figure 1
Flow chart of the selection process for inclusion of Randomised Controlled Trials (RCT) in the overview.
 
Articles obtained in a general very 
sensitive search (n=3181) 
  15 articles selected (13 Randomised Controlled Trials [RCT] (articles 19 
and 21 are from the same trial ) (27 and 28 are from the same trial ) 
 Infliximab 4 RCT (2581 patients) 
19,20,21,22, 23 references 
 Etanercept 4 RCT (1637 patients) 
24,25,26,27,28 references 
 Adalimumab 5 RCT (2869 patients) 
29,30,31,32,33 references 
31 articles excluded: 
Open study 8 (34-41 references) 
Under 6 month duration 8 (42-49 references) 
Administration type 3 (50-52 references) 
Quality of life and functional status 3 (53-55 ) 
Subanalisis 2 ( 56,57) 
Other reasons 7 (58-64 references) 
Potentially relevant articles for 
more detailed evaluation (n=46) 
Articles excluded on the basis of 
title and/or abstract (n=3135) B
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Table 1: Summary of trials included in the metaanalysis
Trial (reference) Comparisons 
Jadad's scale (J)
Groups and N of patients Mean age 
(years)
Mean disease 
duration (years)
N of swollen 
joints
N of tender 
joints
CRP 
(mg/dl)
HAQ Mean N of previous 
DMARDs
Previous response to 
MTX
Lipsky et al. (19) Infliximab+MTX vs. MTX 
J [5]
3 mg/Kg 8 wk * 86 54 10 22 32 3.9 1.8 3.8 Insufficient
3 mg/Kg 4 wk 86 52 9 21 31 3.5 1.7 2.6
10 mg/Kg 8 wk 87 54 11 23 32 3.3 1.7 2.5
10 mg/Kg 4 wk 81 52 12 24 34 4.2 1.7 2.5
MTX 88 51 11 21 31 4.0 1.7 2.5
total 428
St. Clair et al. (20) Infliximab+MTX vs. 
MTX J [3]
3 mg/Kg 8 wk * 373 51 0,8 21 32 2.9 1,5 71% Not previously MTX
6 mg/Kg 8 wk 378 50 0,9 22 33 3.0 1,5 68%
MTX 298 50 0,9 22 34 2.6 1,5 65%
total 1049 DMARDs naive
Quinn et al. (22) Infliximab+MTX vs. MTX 
J [3]
3 mg/Kg 8 wk * 10 51 0,6 NA NA 4.7 1,3 Not previously DMARDs Not previously MTX
MTX 10 53 0,5 3.7 1.3
total 20
Westhovens et al. (23) Infliximab+MTX vs. 
MTX J [4]
3 mg/Kg 8 wk * 360 53 7.8 15 22 1.6 1.5 NA Insufficient
10 mg/Kg 8 wk * 361 52 6.3 15 22 1.6 1.5
MTX 363 52 8.4 15 22 1.2 1.5
total 1084
Moreland et al. (24) Etanercept vs. placebo 
J [5]
25 mg twice weekly * 78 11 25 33 4.7 1.6 3.3 Insufficient
10 mg twice weekly 76 53 13 25 34 5.3 1.7 3.4
placebo 80 53 12 25 35 4.1 1.7 3.0
total 234 51
Weinblatt et al. (25) Etanercept+MTX vs. 
MTX J [3]
25 mg twice weekly * 59 13 20 28 2.2 1.5 2.7 Insufficient
MTX 30 13 17 28 2.6 1.5 2.8
total 89 48
53
Bathon et al. (26) Etanercept vs. MTX J [2] 25 mg twice weekly * 207 51 1 24 31 3.3 NA 0.5 Not previously MTX
10 mg twice weekly 208 50 0.9 24 31 4.4 0.5
MTX 217 49 1 24 30 3.7 0.6
total 632
van der Heijde et al. (28) (TEMPO) 
Etanercept+MTX vs. MTX vs. Etanercept J 
[4]
25 mg twice weekly +MTX * 231 7 22 34 2.9 NA 2.3
25 mg twice weekly * 223 6 23 35 2.2 2.3
MTX 228 52 7 22 33 3.5 2.3
total 682 53
53
Weinblatt et al. (29) (ARMADA) 
Adalimumab+MT X vs. MTX J [3]
40 mg/2 wk * 67 57 12 17 28 2.1 1.5 2.9 Insufficient
20 mg/2 wk 69 53 13 17 28 2.8 1.5 3.0
80 mg/2 wk 73 55 12 17 30 2.8 1.5 3.1
MTX 62 56 11 16 28 3.1 1.6 3.0
total 271B
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van de Putte et al. (30) Adalimumab vs. 
Placebo J [5]
40 mg/2 wk * 113 52 10 20 33 5.2 1.8 3.8 Insufficient
20 mg/2 wk 106 53 9 19 33 5.2 1.8 3.7
20 mg/wk 112 54 11 19 35 4.7 1.8 3.6
40 mg/wk 103 51 11 19 33 4.9 1.8 3.8
Placebo 110 53 11 19 35 5.7 1.8 3.6
total 544
Furst et al. (31) (STAR) Adalimumab+ 
DMARD vs. DMARD J [3]
40 mg/2 wk * 318 9 20 27 1.5 1.3 57–60% Insufficient
DMARD 318 11 21 27 1.5 1.4 2 or plus
total 636 55
55
Keystone et al. (32) Adalimumab+MT X 
vs. MTX J [3]
40 mg/2 wk * 207 56 11 19 27 1.8 1.4 2.4 Insufficient
20 mg/wk 212 57 11 19 27 1.4 1.4 2.4
MTX 200 56 10 19 28 1.8 1.4 2.4
total 619
Breedveld et al. (33) (PREMIER) 
Adalimumab+MT X vs. MTX vs. 
Adalimumab J [4]
40 mg/2 wk + MTX * 268 52 0,7 21 31 NA 1.5 NA Not previously MTX
40 mg/2 wk 274 52 0,7 22 32 1.6
MTX 257 52 0,8 22 32 1.5
total 799
*groups receiving doses currently recommended
NA: not available
CRP: C-reactive protein
HAQ: health assessment questionnaire
Table 1: Summary of trials included in the metaanalysis (Continued)BMC Musculoskeletal Disorders 2008, 9:52 http://www.biomedcentral.com/1471-2474/9/52
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ought not to have been treated with MTX previously. The
trial lasted 1 year (with information at 6 and 12 months)
and MTX was administered in a rapid dose-increasing
schedule (initial dose 7.5 mg/wk, increased to 15 mg/wk
at week 4 and 20 mg/wk at week 8). The TEMPO trial [28]
included 682 patients with RA and insufficient DMARD
responses. Around 40% had previously received MTX (but
patients previously treated with MTX had neither discon-
tinued it owing to toxicity nor been treated with MTX
within 6 months of enrolment). The trial lasted 2 years.
MTX was administered in a rapid dose-increasing sched-
ule to 20 mg/wk in 8 weeks. The main goal of this study
was to demonstrate that etanercept was capable of inhib-
iting the progression of structural joint damage.
There were five adalimumab trials. The ARMADA trial
(The Anti-tumour necrosis factor Research study pro-
gramme of the Monoclonal Antibody adalimumab in
rheumatoiD Arthritis) [29] compared the efficacy of 6
months' treatment with adalimumab plus MTX with MTX
alone in 271 patients with insufficient responses to MTX
and at least one other DMARD. The van de Putte et al. trial
[30] compared the efficacy of adalimumab with a placebo
after 6 months treatment. All 544 patients included had
inadequate responses to MTX and 3 other DMARDs. The
basic purpose of the STAR trial (Safety Trial of Adalimu-
mab in Rheumatoid arthritis) [31] was to study adalimu-
mab safety. It recruited 636 patients with inadequate
responses to any DMARD who were subsequently ran-
domised either to continue with their current DMARD
alone or to use a combination of the DMARD with adali-
mumab for 6 months. The Keystone et al. [32] trial had a
similar design to ARMADA with a 12-month duration
(information at 6 and 12 months), comparing adalimu-
mab plus MTX with MTX alone in 619 patients. The basic
purpose of this study was to demonstrate that adalimu-
mab could inhibit the progression of structural joint dam-
age. The PREMIER trial [33] compared the efficacies of
adalimumab, adalimumab plus MTX and MTX alone in
799 patients at 24 months without previous treatment
with MTX.
For each selected trial we extracted data on major features
of the study design and characteristics of the patients
included (Table 1). Weekly doses of MTX administered to
the patients during the trials averaged 16 mg, except for
the St. Clair et al. [20], TEMPO [28]. Bathon et al. [26] and
PREMIER trials [33], in which MTX was administered in a
rapid dose-increasing schedule to 20 mg/wk. The clinical
profile of RA also varied across trials. Patients had a long
history of RA (around 10 years) in most trials but a shorter
evolution time in four of them: under 3 years in the St.
Clair et al. [20], Bathon et al. [26] and Quinn et al. [22]
and PREMIER [33] trials and around 6 years in the
TEMPO [28] study. Therapeutic use of MTX prior to enrol-
ment in the trial was also considered, because failure of or
inadequate response to prior MTX administration entails
a low response rate in the control group.
Metaanalysis results
Efficacy of anti-TNFα drugs. Global analysis
We studied the efficacies of the anti-TNFα drugs in the 13
trials included [19-33] (Table 2). Global comparison of
the ACR20 efficacy of any dose of any anti-TNFα drug
with any control treatment showed a combined effect of
1.81 (95% CI 1.43–2.29) with an NNT of 6 (5–7). The
combined effects were 1.89 (1.30–2.75) for adalimumab
trials, 1.71 (1.11–2.63) for etanercept trials and 1.82
(1.19–2.77) for infliximab trials. Further analyses using
ACR50 and ACR70 efficacies showed very similar results
(Figure 2).
Analysis of this set of 13 trials provided evidence of rele-
vant and statistically significant heterogeneity (Q = 157.7;
p < 0.001; I2 92%). Although the limited number of trials
reduced the discriminatory power of the funnel plot, it
suggested a certain degree of asymmetry (Figure 3), which
was statistically confirmed by both the Begg and Mazum-
dar adjusted rank correlation test (p = 0.033) and Egger's
regression asymmetry test (p = 0.001).
Bearing all these aspects in mind, we focused on the anal-
ysis of subgroups that appeared more homogeneous on
both clinical and trial design grounds: previous exposure
and response to DMARDs, mainly MTX, dose of anti-
TNFα drug administered and control treatment selected
(active or placebo, single or combined). The effects (RR)
obtained with different doses of anti-TNFα appear in
Table 3. The distinct NNTs and the analysis of heterogene-
ity appear in Table 4. Evidently the specific subgroups of
trials characterised by these features are much less hetero-
geneous on analysis.
Efficacy of anti-TNFα drugs depending on prior exposure and 
response to MTX
The efficacy results (Figure 4) show that this factor leads
to rather different estimates and should be taken into
account. When the effect of an anti-TNFα drug is assessed
in patients who have received no previous MTX treatment,
the relative ACR20 effect is small and only marginally sta-
tistically significant: 1.10 (0.96–1.26). On the other hand,
when the anti-TNFα drug effect is analysed in patients
with previously insufficient responses to MTX, the relative
effect is substantially larger (2.32 [1.99–2.72]) and both
clinically relevant and statistically significant [NNT of 4
(3–5)]. Similar results are seen with the ACR50 and
ACR70 responses, though here the effect in patients naïve
to MTX is statistically significant compared to control
arms.B
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) Table 2: Efficacy of anti-TNFα drugs on ACR20, ACR50 and ACR70 responses
Trial (reference) Comparisons 
Duration of trial in months
Groups N of 
patients
6 month 
ACR20
6 month 
ACR50
6 month 
ACR70
12 month 
ACR20
12 month 
ACR50
12 month 
ACR70
24 month 
ACR20
24 month 
ACR50
24 month 
ACR70
Lipsky et al. (19) Infliximab+MTX vs. 
MTX 12 months
3 mg/Kg 8 wk +MTX* 86 22/86 7/86 36/86 18/86 9/86
3 mg/Kg 4 wk +MTX 86 43/86 25/86 9/86 41/86 29/86 31/86
10 mg/Kg 8 wk +MTX 87 43/86 27/87 15/87 51/87 34/87 22/87
10 mg/Kg 4 wk +MTX 81 45/87 21/81 9/81 48/81 31/81 15/81
Total Infliximab 340 47/81 95/340 40/340 176/340 112/340 77/340
MTX 88 178/340 4/88 0/88 15/88 7/88 2/88
Total 428 18/88
St. Clair et al. (20) Infliximab+MTX vs. 
MTX 12 months
3 mg/Kg 8 wk +MTX* 373 NA NA 231/373 171/373 123/373
6 mg/Kg 8 wk +MTX 378 249/378 189/378 140/378
Total Infliximab 751 NA 480/751 360/751 263/751
MTX 298 161/298 95/298 62/298
Total 1049
Quinn et al. (22) Infliximab+MTX vs. 
MTX 12 months
3 mg/Kg 8 wk +MTX* 10 8/10 8/10 7/10
MTX 10 NA NA NA 6/10 4/10 3/10
Total 20
Westhovens et al. (23) Infliximab+MTX 
vs. MTX 6 months
3 mg/Kg 8 wk +MTX* 360 110/360 48/360
10 mg/Kg 8 wk +MTX 361 199/360 119/361 54/341
Total Infliximab 721 205/361 229/721 102/721
MTX 363 404/721 33/363 16/363
Total 1084 87/363
oreland et al. (24) Etanercept vs. 
placebo 6 months
25 mg 2 twice weekly * 78 31/78 11/78
10 mg 2 twice weekly 76 46/78 18/76 7/76
Total Etanercept 154 37/76 49/154 18/154
Placebo 80 83/154 4/80 1/80
Total 234 9/80
Weinblatt et al. (25) Etanercept+MTX 
vs. MTX 6 months
25 mg 2 +MTX * 59 42/59 23/59 9/59
MTX 30 8/30 1/30 0/30
Total 89
Bathon et al. (26) ** Etanercept vs. MTX 
12 months
25 mg 2 twice weekly * 207 147/207 NA NA 149/207 101/207 52/207
10 mg 2 twice weekly 208 NA NA NA NA NA NA
Total Etanercept 415 56/217 NA NA 141/217 93/217 47/217
MTX 217
Total 632
van der Heijde et al. (28) (TEMPO) 
Etanercept+MTX vs. etanercept vs 
MTX 24 months
25 mg 2 twice weekly +MTX * 231 NA NA NA 196/231 159/231 99/231 199/231 164/231 113/231
25 mg 2 twice weekly* 223 169/223 107/223 54/223 167/223 120/223 60/223
Total Etanercept 454 365/454 266/454 153/454 386/454 284/454 173/454
MTX 228 171/228 98/228 43/228 162/228 96/228 4/228
Total 682
Weinblatt et al. (29) ARMADA) 
dalimumab+MTX vs. MTX 6 months
40 mg/2 s+MTX* 67 45/67 37/67 18/67
20 mg/2 s+MTX 69 33/69 22/69 7/69
80 mg/2 s+MTX 73 48/73 31/73 14/73
Total Adalimumab 209 126/209 90/209 39/209
MTX 62 9/62 5/62 3/62
Total 271B
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van de Putte et al. (30) Adalimumab vs. 
Placebo 6 months
40 mg/2 wk * 113 25/113 14/113
20 mg/2 wk 106 52/113 20/106 9/106
20 mg/wk 112 38/106 23/112 11/112
40 mg/wk 103 44/112 36/103 19/103
Total Adalimumab 434 55/103 104/434 53/434
Placebo 110 189/434 9/110 2/110
Total 544 21/110
Furst et al. (31) (STAR) 
Adalimumab+DAMAR D vs. DAMARD 
6 months
40 mg/2 wk * 318 93/318 47/318
DMARD 318 169/318 35/318 10/318
Total 636 111/318
Keystone et al. (32) Adalimumab+MTX 
vs. MTX 12 months
40 mg/2 wk +MTX* 207 131/207 80/207 43/207 122/207 86/207 48/207
20 mg/wk +MTX 212 129/212 87/212 36/212 116/212 80/212 44/212
Total Adalimumab 419 260/419 167/419 79/419 238/419 166/419 92/419
MTX 200 59/200 19/200 5/200 48/200 19/200 9/200
Total 619
Breedveld et al. (33) (PREMIER) 
Adalimumab+MTX vs. adalimumab vs 
MTX 24 months
40 mg/2 wk+MTX* 268 NA NA NA 196/268 166/268 123/268 185/268 158/268 126/268
40 mg/2 wk * 274 148/274 112/274 71/274 134/274 101/274 77/274
Total Adalimumab 542 344/542 278/542 194/542 319/542 259/542 203/542
MTX 257 162/257 118/257 72/257 144/257 111/257 72/257
* groups receiving doses currently recommended
NA: not available
Table 2: Efficacy of anti-TNFα drugs on ACR20, ACR50 and ACR70 responses (Continued)BMC Musculoskeletal Disorders 2008, 9:52 http://www.biomedcentral.com/1471-2474/9/52
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Efficacy of all doses of anti-TNFα drugs on ACR20, ACR50 and ACR70 responses Figure 2
Efficacy of all doses of anti-TNFα drugs on ACR20, ACR50 and ACR70 responses. Effect refers to the risk of obtain-
ing the corresponding response with anti-TNFα drug relative to control treatment. 'Lower' and 'upper' represent the 95% con-
fidence interval limits for the efficacy estimate. Random-effect models.
Group by 
Anti- TNF 
Study name  Statistics for each study Events /  Total Risk ratio and 95% CI 
Risk   Lower Upper 
ratio  lim it lim it An ti-TN F Control
A dali mum ab  W einblatt et al. 2003 (29)  4.15  2.25 7.67 126 / 209 9 / 62
Adalimum ab  van de Putte et al, 2004 (30)  2.28  1.53 3.40 189 / 434 21 / 110
Adalimum ab  Furst et al, 2003 (31)  1.52  1.27 1.83 169 / 318 111 / 318
A dali mum ab  Keystone et al, 2004 (32)  2.37  1.82 3.07 238 / 419 48 / 200
A dali mum ab  Breedveld et al, 2006 (33)  1.01  0.90 1.13 344 / 542 162 / 257
A dali mum ab  1.89  1.30 2.75
Etanercept  Moreland et al, 1999 (24)  4.79  2.54 9.02 83 / 154 9 / 80
Etanercept  W einblatt et al, 1999 (25)  2.67  1.44 4.94 42 / 59 8 / 30
Etanercept  Bathon et al, 2000 (26)  1.11  0.97 1.26 149 / 207 141 / 217
Etanercept  van der Heijde et al 2006 (28) 1.07  0.98 1.17 365 / 454 171 / 228
Etanercept  2.06  1.11 3.86
Inflixim ab  Lipsky et al, 2000 (19)  4.14  2.00 8.57 112 / 340 7 / 88
Inflixim ab  St Clair et al, 2004 (20)  1.18  1.05 1.33 480 / 751 161 / 298
Inflixim ab  Quinn et al, 2005 (22)  1.33  0.74 2.41 8 / 10 6 / 10
Inflixim ab  W esthovens et al, 2006 (23)  2.34  1.93 2.84 404 / 721 87 / 363
Inflixim ab  1.82  1.19 2.77
Ov er al l  1.81  1.43 2.29
0,1 0,2 0,5 1  2  5  10 
Control Anti- TNF  
ACR20 response
 
Group by 
Anti-TNF  
Study name  Statistics for each study Events /  Total Risk ratio and 95% CI 
Risk   Lower Upper 
ratio  lim it lim it Anti-TN F Control
Adalimumab  W einblatt et al, 2003 (29)  5.34  2.27 12.55 90 / 209 5 / 62
Adalimumab  van de Putte et al, 2004 (30)  2.93  1.53 5.60 104 / 434 9 / 110
Adalimumab  Furst et al, 2003 (31)  2.66  1.86 3.79 93 / 318 35 / 318
Adalimumab  Keystone et al, 2004 (32)  4.17  2.68 6.50 166 / 419 19 / 200
Adalimumab  Breedveld et al, 2006 (33)  1.12  0.96 1.31 278 / 542 118 / 257
Adalimumab  2.68  1.58 4.56
Etanercept  Moreland et al, 1999 (24)  6.36  2.38 17.00 49 / 154 4 / 80
Etanercept  W einblatt et al, 1999 (25)  11.69  1.66 82.47 23 / 59 1 / 30
Etanercept  Bathon et al, 2000 (26)  1.14  0.93 1.40 101 / 207 93 / 217
Etanercept  van der Heije et al, 2006 (28) 1.39  1.17 1.65 266 / 454 96 / 228
Etanercept  2.11  1.10 4.04
Inflixim ab  Lipsky et al, 2000 (19)  4.14  2.00 8.57 112 / 340 7 / 88
Inflixim ab  St Clair et al, 2004 (20)  1.50  1.25 1.80 360 / 751 95 / 298
Inflixim ab  Quinn et al, 2005 (22)  2.00  0.88 4.54 8 / 10 4 / 10
Inflixim ab  W esthovens et al, 2006 (23)  3.49  2.48 4.92 229 / 721 33 / 363
Inflixim ab  2.51  1.38 4.57
Ov er al l  2.46  1.75 3.45
0,1 0,2 0,5  1  2  5  10
Control Anti-TNF  
ACR50 response
 
Group by 
Anti-TNF 
Study name Statistics for each study Events /  Total Risk ratio and 95% CI 
Risk   Lower Upper 
ratio  lim it lim it Anti-TN F Group-B
Adal i mumab  W einblatt et al. 2003 (29)  3.86  1.23 12.05 39 / 209 3 / 62
Adal i mumab  van de Putte et al, 2004 (30)  6.72  1.66 27.13 53 / 434 2 / 110
Adal i mumab  Furst et al, 2003 (31)  4.73  2.43 9.19 47 / 318 10 / 320
Adal i mumab  Keystone et al, 2004 (32)  4.88  2.51 9.47 92 / 419 9 / 200
Adal i mumab  Breedveld et al. 2006 (33)  1.28  1.02 1.60 194 / 542 72 / 257
Adal i mumab  3.33  1.76 6.29
Etanercept  Moreland et al, 1999 (24)  9.35  1.27 68.78 18 / 154 1 / 80
Etanercept  W einblatt et al, 1999 (25)  9.82  0.59 163.15 9 / 59 0 / 30
Etanercept  Bathon et al, 2000 (26)  1.15  0.81 1.62 52 / 207 47 / 215
Etanercept  van der Heije et al, 2006 (28)  1.79  1.33 2.41 153 / 454 43 / 228
Etanercept  2.02  0.92 4.40
Inflixim ab  Lipsky et al, 2003 (19)  9.96  2.50 39.77 77 / 340 2 / 88
Inflixim ab  St Clair et al, 2004 (20)  1.68  1.32 2.14 263 / 751 62 / 298
Inflixim ab  Quinn et al, 2005 (22)  2.33  0.83 6.54 7 / 10 3 / 10
Inflixim ab  W esthovens et al, 2006 (23)  3.21  1.92 5.35 102 / 721 16 / 363
Inflixim ab  2.86  1.41 5.78
Overall  2.77  1.85 4.15
0,01 0,1 1  10  100
Control  Anti-TNF  
ACR70 responseBMC Musculoskeletal Disorders 2008, 9:52 http://www.biomedcentral.com/1471-2474/9/52
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Analysis of the effect of different doses of anti-TNFα drugs
We analysed the efficacy of anti-TNFα drug administra-
tion in three separate groups: currently recommended
doses (infliximab 3 mg/Kg/8 week; etanercept 25 mg
twice a week; adalimumab 40 mg every 2 weeks); high
doses (infliximab 3 mg/Kg/4 week, 6 mg/Kg/8 week, 10
mg/Kg/8 week and 10 mg/Kg/4 week; adalimumab 40
mg/week, 80 mg/2 week); and low doses (etanercept 10
mg 10 mg twice weekly; adalimumab 20 mg/2 week). No
patient receiving infliximab was prescribed lower than
recommended doses, and no patient treated with etaner-
cept received higher than recommended doses. The group
given adalimumab 20 mg/week was not included as this
dose schedule can be considered neither above nor below
the currently recommended regime. The combined and
individual effects of the adalimumab, etanercept and inf-
liximab trials at any dose or in subgroups based on the
dose level are shown in Table 3. A statistically significantly
beneficial effect is apparent with recommended, higher or
lower doses in all the comparisons made, except for the
ACR70 response to etanercept. Accordingly, the NNTs are
very similar for all anti-TNFα drugs.
Analysis of the effect of anti-TNFα drugs at recommended doses
Five trials [19,23,25,29,32] compared the effects of anti-
TNFα drugs plus MTX with MTX alone in patients with
insufficient responses to MTX. A beneficial combined
effect in the ACR20 response is shown: RR 2.60 (2.05–
3.31) with an NNT of 4 (3–4). Analyses using the ACR50
and ACR70 responses showed very similar results (Figure
5). There was no evidence of statistical heterogeneity
among the different drug classes (Table 4).
Only two trials [24,30] assessed the effect of anti-TNFα
drugs versus placebo, showing a combined positive effect
on the ACR20 response with an RR of 3.42 (1.60–7.30)
and an NNT of 3 (3–4). Although there was a statistically
significant heterogeneity of effects according to which
drug had been used (Q = 3.8; p = 0.049; I2 = 74) with
etanercept apparently more effective than adalimumab
(Figure 6), it should be emphasized that there was no
direct head to head comparison among them. There was
no statistical evidence of heterogeneity in either the
ACR50 or the ACR70 response, but the estimates of the
effect varied widely between the two drugs, with a pattern
similar to that obtained with the ACR20 outcome and
based on a rather small number of patients.
Funnel plot of selected studies Figure 3
Funnel plot of selected studies. The x-axis shows effect estimates (RR) on a logarithmic scale (any effect estimate greater 
than zero therefore indicates better results for experimental treatment) while the y-axis measures the precision of each study 
(as the inverse of the standard error of the effect estimate measured on a logarithmic scale).
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Four trials [20,22,28,33] compared the effect of anti-
TNFα drug plus MTX with MTX alone in patients with no
previous resistance to MTX. This analysis showed a small
but significant combined effect on the ACR20 response of
1.15 (1.07–1.22) with an NNT of 10 (7–16) (Figure 7).
The ACR50 showed a combined effect of 1.56 (1.41–1.72)
whereas that effect was 1.77 (1.52–2.05) for ACR70. No
statistically significant heterogeneity was present for any
of these outcomes.
Three trials compared efficacies of anti-TNFα drugs with
MTX alone as control [26,28,33]. The ACR20 combined
effect showed no significant difference among the arms,
with RR = 1.00 (0.92–1.08). Results were similar for the
ACR50 and ACR70 responses (Figure 8). The heterogene-
ity was marginally significant for ACR20 and significant
for ACR50 (Table 4).
Safety analysis
An overview of the adverse events reported in the selected
trials is displayed in Table 5. The number of withdrawals
due to adverse events according to treatment arm was
reported in all trials. Information on the incidence of seri-
ous infections, malignancies and mortality is also pro-
vided, specifying whether patients were in the
experimental or control arms, but information about the
specific treatment group of the patient was sometimes
lacking. Other important safety information (overall
number of adverse events, severe adverse events, total
number of infections, infusion reactions and injection-
site reactions) was provided much less consistently.
Regarding withdrawals due to adverse events, we found
no significant overall difference between the experimental
and control groups, with a pooled RR of 1.25 (0.65–2.39)
(Figure 9). Results differed depending on the specific anti-
TNFα given: patients in the etanercept arms were less
likely to withdraw from adverse events than their control
counterparts, but the opposite was the case for adalimu-
mab and infliximab, all those comparisons reaching sta-
tistical significance. There was statistically significant
heterogeneity among the drugs (Q = 29.3; p = 0.003; I2
59) but not within the groups given each specific drug.
The results were the same when only groups receiving rec-
ommended doses of anti-TNFα drugs were studied.
Higher than recommended doses of infliximab led to a
higher withdrawal rates. There were no significant differ-
ences in withdrawal rates between lower than recom-
mended dose and control arms.
There were more adverse events in patients allocated to
anti-TNFα drugs (RR 1.02 (1.00–1.04)) (p = 0.021) (Table
6). Patients receiving infliximab showed a higher fre-
quency of serious adverse events (p = 0.048) and infec-
tions (p = 0.004), but the combined estimates for all three
anti-TNFα drugs and safety outcomes were not significant.
Information on severe infections, malignancies and
deaths was provided in all trials except for severe infec-
Table 3: Effects (RR and NNT (95% CI)) obtained with different doses of anti-TNFα drugs
All doses of anti-TNFα drugs 
vs. control 4618 vs. 2261*
Recommended doses of anti-
TNFα drugs vs. control 2874 
vs. 2260**
High-doses drugs vs. control 
1169 vs. 921*** of anti-TNFα
Low-doses of anti-TNFα 
drugs vs. control 251 vs. 
252****
Anti-TNFα ACR RR (CI 95%) NNT RR (CI 95%) NNT RR (CI 95%) NNT RR (CI 95%) NNT
Adalimumab ACR20 1.9 (1.3–2.8) 6 (5–7) 2.0 (1.3–2.9) 5 (4–6) 3.5 (1.6–7.3) 3 (2–4) 2.4 (1.4–4.1) 5 (4–8)
ACR50 2.7 (1.6–4.4) 6 (5–7) 2.8 (1.6–4.7) 5 (5–6) 4.7 (1.9–12.0) 4 (3–5) 2.9 (1.6–5.1) 7 (5–13)
ACR70 3.3 (1.8–6.3) 9 (7–11) 3.5 (1.9–6.7) 7 (6–8) 6.1 (1.8–20.8) 7 (5–11) 3.0 (1.1–7.9) 17 (9–77)
Etanercept ACR20 1.7 (1.1–2.6) 7(5–10) 1.7 (1.1–2.7) 6 (5–8) There are no trials with high 
doses of Etanercept
4.3 (1.9–10.1) 3 (2–5)
ACR50 2.1 (1.1–3.9) 6 (5–9) 2.2 (1.1–4.3) 6 (4–7) 4.7 (1.7–13.4) 6 (4–13)
ACR70 2.0 (0.9–4.4) NS 2.1 (0.9–4.5) NS 7.4 (0.9–58.5) NS
Infliximab ACR20 1.8 (1.2–2.8) 5 (4–6) 1.7 (1.1–2.6) 5 (4–6) 2.0 (1.2–3.6) 5 (4–5) There are no trials with low 
doses of Infliximab
ACR50 2.6 (1.5–4.7) 5 (5–6) 2.2 (1.2–4.1) 6 (5–7) 2.8 (1.5–5.5) 5 (4–6)
ACR70 2.9 (1.4–5.8) 8 (6–10) 2.4 (1.2–5.0) 9 (7–13) 3.3 (1.5–7.2) 7 (6–7)
Overall ACR20 1.8 (1.4–2.3) 6 (5–7) 1.8 (1.4–2.3) 5 (5–6) 2.5 (1.5–4.2) 4 (5–4) 2.9 (1.7–5.1) 4 (3–6)
ACR50 2.5 (1.8–3.4) 6 (5–6) 2.4 (1.7–3.4) 5 (5–6) 3.4 (2.0–5.8) 5 (4–5) 3.2 (2.0–5.3) 6 (5–10)
ACR70 2.8 (1.9–4.2) 8 (7–9) 2.7 (1.8–4.1) 7 (7–9) 3.9 (2.0–7.6) 7 (6–8) 3.5 (1.4–8.6) 15 (10–38)
NNT: number of patients needed to be treated
RR (95%CI): relative risk (95% confidence limits)
NS: non-significant results
*4618 patients being treated with anti-TNFα (except 208 patients Bathon's trial being treated with 10 mg of etanercept twice a week) vs 2261 patients of the control groups
**2874 patients with recommended doses of anti-TNFα drugs (Infliximab 3 mg/Kg/8 week; etanercept 25 mg twice a week; adalimumab 40 mg every 2 weeks) vs 2260 
patients of the control groups
***1169 patients with high-doses of anti-TNFα drugs (infliximab 3 mg/Kg 4 week, 6 mg/Kg 8 week, 10 mg/Kg 8 week and 10 mg/Kg 4 week; adalimumab 40 mg/week, 80 mg/
2 week) vs 921 patients of the control groups
****251 patients with low-doses of anti-TNFα drugs (etanercept 10 mg twice weekly; adalimumab 20 mg/2 week) vs 252 patients of the control groupsBMC Musculoskeletal Disorders 2008, 9:52 http://www.biomedcentral.com/1471-2474/9/52
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tions in the Bathon trial. No significant combined
increases in risk were seen for any of these results.
We also inquired whether higher than recommended
doses are associated with higher incidences of adverse
events. The reported data were incomplete, however, as
the Lipsky et al. trial [19] did not assign the 22 severe
infections detected to each corresponding infliximab dose
arm. The risk of severe infection when receiving high
doses of infliximab [20,23] was significantly increased (p
= 0.006) with an NNH of 40 (26–91), but the risk of
developing malignancies was not increased (p = 0.116).
Nor did the two trials [29,30] administering high doses of
adalimumab report the dose received by patients experi-
encing severe infections.
Discussion
This study approached a problem of major clinical and
socio-economic importance: the efficacy and safety of
anti-TNFα drugs in the treatment of rheumatoid arthritis
Table 4: Efficacy and heterogeneity
Comparisons (Anti-TNFα vs. 
control)***
ACR response Anti-TNFα Events/Total Control Events/Total RR (CI 95%) NNT Q I2%
All doses of anti-TNFα drugs vs. 
control (4618 vs. 2261)
ACR20 2709/4618 941/2261 1.8 (1.4–2.3) 6 (5–7) 157.7* 92
ACR50 1879/4618 519/2261 2.5 (1.8–3.4) 6 (5–6) 109.8* 89
ACR70 1106/4618 2.8 (1.9–4.1) 8 (7–9) 52.4* 77
Recommended doses of anti-
TNFα drugs vs. control (2874 vs. 
2260)
ACR20 1808/2874 949/2261 1.8 (1.4–2.3) 5 (5–6) 149.5* 92
ACR50 1247/2874 519/2261 2.4 (1.7–3.4) 5 (5–6) 102.9* 88
ACR70 733/2874 270/2261 2.7 (1.8–4.1) 7 (7–9) 49.2* 76
High-doses of anti-TNFα drugs vs. 
control (1169 vs. 921)
ACR20 697/1169 293/921 2.5 (1.5–4.2) 4 (4–5) 57.2* 93
ACR50 469/1169 149/921 3.4 (2.0–5.8) 5 (4–5) 30.5* 87
ACR70 295/1169 85/921 3.9 (2.0–7.6) 7 (6–8) 16.6* 76
Low-doses of anti-TNFα drugs vs. 
control (251 vs. 252)
ACR20 108/251 39/252 2.9 (1.7–5.1) 4 (3–6) 4.9 59
ACR50 60/251 18/252 3.2 (2.0–5.3) 6 (5–10) 1.5 0
ACR70 23/251 6/252 3.5 (1.4–8.6) 15 (10–38) 1.2 0
Anti-TNFα drugs vs. control in 
patients with No insufficient 
response to MTX (1964 vs. 1010)
ACR20 1346/1964 641/1010 1.1 (0.9–1.3) NS 2.4 9
ACR50 1013/1964 408/1010 1.3 (1.1–1.5) 9 (7–13) 8.8 55
ACR70 669/1964 227/1010 1.5 (1.3–1.7) 12 (9–19) 7.0 43
Anti-TNFα drugs vs. control in 
patients with insufficient response 
to MTX (2654 vs. 1251)
ACR20 1427/2654 308/1251 2.3 (2.0–2.7) 4 (3–5) 28.2* 75
ACR50 866/2654 113/1251 3.6 (2.9–4.4) 5 (4–5) 7.2 3
ACR70 437/2654 43/1251 4.4 (3.2–6.0) 7 (6–8) 4.2 0
Anti-TNFα drugs at 
recommended doses plus MTX vs. 
MTX alone in patients with 
insufficient response to MTX (779 
vs. 743)
ACR20 444/779 167/743 2.6 (2.1–3.3) 3 (3–4) 4.3 7
ACR50 274/779 65/743 4.1 (2.6–6.6) 4 (4–5) 4.6 13
ACR70 132/779 30/743 4.1 (2.4–7.1) 8 (7–11) 2.5 0
Anti-TNFα drugs versus placebo 
at recommended doses (191 vs. 
190)
ACR20 98/191 30/190 3.4 (1.6–7.3) 3 (3–4) 3.8* 74
ACR50 56/191 13/190 4.4 (1.5–12.5) 5 (4–7) 2.9 66
ACR70 25/191 3/190 8.1 (2.5–26.4) 9 (7–16) 0.1 0
Anti-TNFα drugs at 
recommended doses plus MTX 
versus MTX alone in patients with 
no previous resistance to MTX 
(882 vs. 793)
ACR20 631/882 500/793 1.2 (1.1–1.2) 10 (7–16) 0.4 0
ACR50 504/882 315/793 1.6 (1.4–1.7) 6 (5–8) 1.1 0
ACR70 352/882 180/793 1.8 (1.5–2.1) 6 (5–8) 3.9 23
Anti-TNFα drugs versus MTX at 
recommended doses (704 vs. 702)
ACR20 466/704 474/702 1.0 (0.9–1.1) NS 6.9* 71
ACR50 320/704 309/702 1.0 (0.9–1.2) NS 3.6 45
ACR70 177/704 162/702 1.1 (0.9–1.3) NS 2.2 11
RR (95%CI): relative risk (95% confidence limits)
NNT: number of patients needed to be treated
Q: Cochrane's Q
I2: percentage of variability in study results attributable to between-study differences
* statistical heterogeneity
NS: non-significant results
*** number of patients being treated with anti-TNFα versus number of patients in the control groupsBMC Musculoskeletal Disorders 2008, 9:52 http://www.biomedcentral.com/1471-2474/9/52
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Efficacy of anti-TNFα drugs depending on an insufficient response to MTX prior to trial commencement Figure 4
Efficacy of anti-TNFα drugs depending on an insufficient response to MTX prior to trial commencement. Effect 
refers to risk of obtaining the corresponding response with anti-TNFα drug relative to control treatment. 'Lower' and 'Upper' 
represent the 95% confidence interval limits for the efficacy estimate. Random-effect models.
Group by 
previous MTX 
Study name  Statistics for each study Events / Total Risk ratio and 95% CI 
Risk   Lower Upper 
ratio  limit limit Anti-TNF Control
No  St Clair et al, 2004 (20)  1.18  1.05 1.33 480 / 751 161 / 298
No  Quinn et al, 2005 (22)  1.33  0.74 2.41 8 / 10 6 / 10
No  Bathon et al, 2000 (26)  1.11  0.97 1.26 149 / 207 141 / 217
No  van der Heije et al, 2006 (28)  1.07  0.98 1.17 365 / 454 171 / 228
No  Breedveld et al, 2006 (33)  1.01  0.90 1.13 344 / 542 162 / 257
No  1.10  0.96 1.26
Yes  Lipsky et al, 2000 (19)  3.04  1.89 4.87 176 / 340 15 / 88
Yes  W esthovens et al, 2006 (23)  2.34  1.93 2.84 404 / 721 87 / 363
Yes  Moreland et al, 1999 (24)  4.79  2.54 9.02 83 / 154 9 / 80
Yes  W einblatt et al, 1999 (25)  2.67  1.44 4.94 42 / 59 8 / 30
Yes  W einblatt et al, 2003 (29)  4.15  2.25 7.67 126 / 209 9 / 62
Yes  van de Putte et al, 2004 (30)  2.28  1.53 3.40 189 / 434 21 / 110
Yes  Furst et al, 2003 (31)  1.52  1.27 1.83 169 / 318 111 / 318
Yes  Keystone et al, 2004 (32)  2.37  1.82 3.07 238 / 419 48 / 200
Yes  2.32  1.99 2.72
0,1 0,2 0,5  1  2  5  10
Control  Anti-TNF  
ACR20 response
 
 
Group by 
Previous MTX 
Study name  Statistics for each study Events /  Total Risk ratio and 95% CI 
Risk   Lower Upper 
ratio  lim it lim it Anti-TNF Control
No  St Clair et al, 2004 (20)  1.50  1.25 1.80 360 / 751 95 / 298
No  Quinn et al, 2005 (22)  2.00  0.88 4.54 8 / 10 4 / 10
No  Bathon et al, 2000 (26)  1.14  0.93 1.40 101 / 207 93 / 217
No  van der Heijde et al, 2006 (28) 1.36  1.15 1.61 266 / 454 98 / 228
No  Breedveld et al, 2006 (33)  1.12  0.96 1.31 278 / 542 118 / 257
Not  1.29  1.12 1.47
Yes  Lipsky et al, 2000 (19)  4.14  2.00 8.57 112 / 340 7 / 88
Yes  W esthovens et al, 2006 (23)  3.49  2.48 4.92 229 / 721 33 / 363
Yes  Moreland et al, 1999 (24)  6.36  2.38 17.00 49 / 154 4 / 80
Yes  W einblatt et al, 1999 (25)  11.69  1.66 82.47 23 / 59 1 / 30
Yes  W einblatt et al, 2003 (29)  5.34  2.27 12.55 90 / 209 5 / 62
Yes  van de Putte et al, 2004 (30)  2.93  1.53 5.60 104 / 434 9 / 110
Yes  Furst et al, 2003 (31)  2.66  1.86 3.79 93 / 318 35 / 318
Yes  Keystone et al, 2004 (32)  4.17  2.68 6.50 166 / 419 19 / 200
Yes  3.57  2.90 4.40
0,01 0,1 1  10  100
Control  Anti-TNF  
ACR50 response
 
 
 
 
Group by 
previous MTX 
Study name Statistics for each study Events /  Total Risk ratio and 95% CI 
Risk   Lower Upper 
ratio  lim it lim it Anti- TNF Control
No  St Clair et al, 2004 (20)  1.68  1.32 2.14 263 / 751 62 / 298
No  Q uinn et al, 2005 (22)  2.33  0.83 6.54 7 / 10 3 / 10
No  Bathon et al, 2000 (26)  1.15  0.81 1.62 52 / 207 47 / 217
No  van der Heijde et al, 2006 (28)  1.79  1.33 2.41 153 / 454 43 / 228
No  Breedveld et al, 2006 (33)  1.28  1.02 1.60 194 / 542 72 / 257
No  1.51  1.32 1.72
Yes  Lipsky et al, 2000 (19)  9.96  2.50 39.77 77 / 340 2 / 88
Yes  W esthovens et al, 2006 (23)  3.21  1.92 5.35 102 / 721 16 / 363
Yes  Moreland et al, 1999 (24)  9.35  1.27 68.78 18 / 154 1 / 80
Yes  W einblatt et al, 1999 (25)  9.82  0.59 163.15 9 / 59 0 / 30
Yes  W einblatt et al, 2003 (29)  3.86  1.23 12.05 39 / 209 3 / 62
Yes  van de Putte et al, 2004 (30)  6.72  1.66 27.13 53 / 434 2 / 110
Yes  Furst et al, 2003 (31)  4.73  2.43 9.19 47 / 318 10 / 318
Yes  Keystone et al, 2004 (32)  4.88  2.51 9.47 92 / 419 9 / 200
Yes  4.41  3.24 6.00
0,01 0,1  1  10  100
Control  Anti- TNF  
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Efficacy of anti-TNFα drugs at recommended doses in combination with MTX compared with MTX alone in patients with  insufficient responses to MTX Figure 5
Efficacy of anti-TNFα drugs at recommended doses in combination with MTX compared with MTX alone in 
patients with insufficient responses to MTX. Effect refers to risk of obtaining the corresponding response with anti-
TNFα drug relative to control treatment. 'Lower' and 'Upper' represent the 95% confidence interval limits for the efficacy esti-
mate. Random-effect models.
Group by 
Anti-TNF 
Study name Statistics for each study Events / Total Risk ratio and 95% CI 
Risk   Lower Upper 
ratio  lim it lim it Anti-TNF Control
A dalim um ab  W einblatt et al, 2003 (29)  4.63  2.47 8.66 45 / 67 9 / 62
A dalim um ab  Keystone et al, 2004 (32)  2.46  1.87 3.22 122 / 207 48 / 200
A dalim um ab  2.93  2.00 4.29
Etanercept  W einblatt et al, 1999 (25)  2.67  1.44 4.94 42 / 59 8 / 30
Etanercept  2.67  1.31 5.44
Inflixim ab  Lipsky et al, 2000 (19)  2.46  1.45 4.15 36 / 86 15 / 88
Inflixim ab  W esthovens et al, 2006 (23)  2.31  1.88 2.83 199 / 360 87 / 363
Inflixim ab  2.35  1.66 3.32
Ov eral l  2.60  2.05 3.31
0,1 0,2 0,5  1  2  5  10
Control  Anti- TNF  
ACR20 response 
 
Group by 
Ant i- TNF 
Study name Statistics for each study Events /  Total Risk ratio and 95% CI 
Risk   Lower Upper 
ratio  lim it lim it Anti - TNF Control
Adalim um ab  W einblatt et al, 2003 (29)  6.85  2.88 16.31 37 / 67 5 / 62
Adalim um ab  Keystone et al, 2004 (32)  4.37  2.77 6.91 86 / 207 19 / 200
Adalim um ab  4.82  3.22 7.22
Etanercept  W einblatt et al, 1999 (25)  11.69  1.66 82.47 23 / 59 1 / 30
Etanercept  11.69  1.66 82.47
Inflixim ab  Lipsky et al, 2000 (19)  2.63  1.16 5.98 18 / 86 7 / 88
Inflixim ab  W esthovens et al, 2006 (23)  3.36  2.34 4.82 110 / 360 33 / 363
Inflixim ab  3.23  2.32 4.49
Overall  4.13  2.59 6.59
0,01 0,1 1  10  100
Control  Anti - TNF  
ACR50 response 
 
 
Group by 
Anti-TNF 
Study name Statistics for each study Events / Total Risk ratio and 95% CI 
Risk   Lower Upper 
ratio  limit limit Anti-TNF Group-B
Adalimumab  W einblatt et al, 2003 (29)  5.55  1.72 17.93 18 / 67 3 / 62
Adalimumab  Keystone et al, 2004 (32)  5.15  2.60 10.22 48 / 207 9 / 200
Adalimumab  5.25  2.91 9.49
Etanercept  W einblatt et al, 1999 (25)  9.82  0.59 163.15 9 / 59 0 / 30
Etanercept  9.82  0.59 163.15
Inflixim ab  Lipsky et al, 2000 (19)  4.60  1.02 20.70 9 / 86 2 / 88
Inflixim ab  W esthovens et al, 2006 (23)  3.02  1.75 5.23 48 / 360 16 / 363
Inflixim ab  3.18  1.90 5.31
Overall  4.14  2.43 7.05
0,01 0,1 1  10  100
Control  Anti-TNF  
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Efficacy of anti-TNFα drugs versus placebo at recommended doses Figure 6
Efficacy of anti-TNFα drugs versus placebo at recommended doses. Effect refers to risk of obtaining the correspond-
ing response with anti-TNFα drug relative to control treatment. 'Lower' and 'Upper' represent the 95% confidence interval 
limits for the efficacy estimate. Random-effect models.
Group by 
Ant i - TNF  
St udy name St at i st i cs f or each st udy Event s /  Tot al Ri sk rat i o and 95% CI 
Ri sk   Lower Upper 
ratio  lim it lim it A n ti-TN F Cont rol
Adal i m um ab  van de Put t e et  al ,  2004 (30)  2. 41  1. 56 3. 72 52 /  113 21 /  110
Adal i m um ab  2. 41  1. 56 3. 72
Et aner cept  M orel and et  al ,  1999 ( 24)  5. 24  2. 76 9. 97 46 /  78 9 /  80
Et aner cept  5. 24  2. 76 9. 97
Ov er al l  3. 42  1. 60 7. 30
0, 1 0, 2 0, 5  1  2  5  10
Cont rol  Ant i - TNF  
ACR20 r esponse 
Group by 
Ant i - TNF 
Study name Stati sti cs f or each study Events /  Total Ri sk rat io and 95% CI 
Ri sk   Lower Upper 
ratio  lim it lim it Anti - TNF Cont rol
Adalim um ab  van de Put t e et  al , 2004 ( 30)  2. 704  1. 322 5.529 25 /  113 9 / 110
Adalim um ab  2. 704  1. 322 5.529
Et anercept  Morel and et al ,  1999 (24)  7. 949  2. 943 21.467 31 / 78 4 /  80
Et anercept  7. 949  2. 943 21.467
Ov er al l  4. 378  1. 531 12.518
0, 01 0, 1 1  10  100
Cont rol  Ant i - TNF  
ACR50 response 
 
Group by 
Anti-TNF 
Study name Statistics for each study Events / Total Risk ratio and 95% CI 
Risk   Lower Upper 
ratio  limit limit Anti-TNF Control
A dalimumab  van de Putte et al, 2004 (30)  6.81  1.59 29.29 14 / 113 2 / 110
A dalimumab  6.81  1.59 29.29
Etanercept  Moreland et al, 1999 (24)  11.28  1.49 85.32 11 / 78 1 / 80
Etanercept  11.28  1.49 85.32
Overall  8.10  2.48 26.43
0,01 0,1 1  10  100
Control  Anti-TNF  
ACR70 response BMC Musculoskeletal Disorders 2008, 9:52 http://www.biomedcentral.com/1471-2474/9/52
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Efficacy of anti-TNFα drugs plus MTX compared to MTX alone in patients with no previous resistance to MTX (at the recom- mended doses) Figure 7
Efficacy of anti-TNFα drugs plus MTX compared to MTX alone in patients with no previous resistance to MTX 
(at the recommended doses). Effect refers to risk of obtaining the corresponding response with anti-TNFα drug relative 
to control treatment. 'Lower' and 'Upper' represent the 95% confidence interval limits for the efficacy estimate. Random-effect 
models.
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Adalimum ab  Breedveld et al, 2006 (33)  1.16  1.03 1.31 196 / 268 162 / 257
Adalimum ab  1.16  1.03 1.31
Etanercept  van der Heijde et al, 2006 (28)  1.13  1.03 1.24 196 / 231 171 / 228
Etanercept  1.13  1.03 1.24
Inflixim ab  St Clair et al, 2004 (20)  1.15  1.01 1.31 231 / 373 161 / 298
Inflixim ab  Quinn et al, 2005 (22)  1.33  0.74 2.41 8 / 10 6 / 10
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Adalimum ab  Breedveld et al, 2006 (33)  1.59  1.36 1.85 166 / 268 118 / 257
Adalimum ab  1.59  1.36 1.85
Etanercept  van der Heijde et al, 2006 (28)  1.60  1.35 1.90 159 / 231 98 / 228
Etanercept  1.69  1.42 2.00
Inflixim ab  St Clair et al, 2004 (20)  1.44  1.18 1.76 171 / 373 95 / 298
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Adalimumab  Breedveld et al, 2006 (33)  1.64  1.29 2.07 123 / 268 72 / 257
Adalimumab  1.64  1.29 2.07
Etanercept  van der Heijde et al, 2006 (28)  2.27  1.67 3.09 99 / 231 43 / 228
Etanercept  2.27  1.67 3.09
Inflixim ab  St Clair et al, 2004 (20)  1.58  1.22 2.07 123 / 373 62 / 298
Inflixim ab  Quinn et al, 2005 (22)  2.33  0.83 6.54 7 / 10 3 / 10
Inflixim ab  1.62  1.26 2.10
Overall  1.77  1.52 2.05
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Efficacy of anti-TNFα drugs compared to MTX at recommended doses Figure 8
Efficacy of anti-TNFα drugs compared to MTX at recommended doses. Effect refers to risk of obtaining the corre-
sponding response with anti-TNFα drug relative to control treatment. 'Lower' and 'Upper' represent the 95% confidence 
interval limits for the efficacy estimate. Random-effect models.
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Adalimumab Breedveld et al, 2006 (33) 0.89 0.73 1.08 112 / 274 118 / 257
Adalimumab 0.89 0.73 1.08
Etanercept Bathon et al, 2000 (26) 1.14 0.93 1.40 101 / 207 93 / 217
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Table 5: Number of patients who presented adverse effects in trials with anti TNFα drugs
Trial (reference) Anti-TNFα 
drug
Groups N of 
patients
Withdrawn 
adverse event
Total adverse 
events
Serious adverse 
events
Infections Serious 
infections
Infusion 
reactions
Injection- site 
reactions
Malignancies Mortality
Lipsky et al. (19) Infliximab 3 mg/Kg 8 86 5 _ _ _ _ _ _
wk +MTX 86 9 _ _ _ _ _ _
3 mg/Kg 4 87 4 _ _ _ _ _ _
wk +MTX 81 8 _ _ _ _ _ _
10 mg/Kg 8 340 26 323 58 244 22 5 5
wk +MTX 88 7 83 18 53 7 NA 0 3
10 mg/Kg 4
wk +MTX
Total
Infliximab
MTX
St. Clair et al. (20) Infliximab 3 mg/Kg 8 373 34 _ _ 21 _ 0 1
wk +MTX 378 35 _ _ 19 _ 4 1
6 mg/Kg 8 751 69 103 414 40 135 4 2
wk +MTX 298 9 NA 32 141 6 20 0 2
Total
Infliximab
MTX
Quinn et al. (22) Infliximab 3 mg/Kg 8 10 1 1 0 1 0 0
wk +MTX 10 0 NA 0 NA 0 0 0 0
MTX
Westhovens et al. (23) Infliximab 3 mg/Kg 8 360 18 _ _ 6 2 0
wk +MTX 361 20 _ _ 18 2 2
10 mg/Kg 8 721 38 512 55 24 4 2
wk +MTX 363 8 239 27 NA 6 NA 1 1
Total
Infliximab
MTX
Moreland et al. (24) Etanercept 25 mg twice 78 2 0 _ 0 0
weekly 76 5 0 _ 0 0
10 mg twice 154 7 0 71 0 0
weekly 80 3 NA NA NA 0 10 0 0
Total
Etanercept
Placebo
Weinblatt et al. (25) Etanercept 25 mg twice 59 2 30 0 23 0 0
weekly 30 1 NA NA 19 0 2 0 0
+MTX MTX
Bathon et al. (26) Etanercept 25 mg twice 207 11 _3 1
weekly 208 12 _2 1
10 mg twice 415 23 140 5 2
weekly 217 24 NA NA NA NA 16 2 0
Total
Etanercept
MTX
van der Heijde et al. (28) (TEMPO) 
Etanercept
25 mg twice 231 37 _ _ _ 23 5 1
weekly 223 34 _ _ _ 24 5 1
+MTX 454 71 379 64 285 47 69 10 2
25 mg twice 228 47 185 37 147 25 4 2 1
weekly
Total
Etanercept
MTXB
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Weinblatt et al. (29) (ARMADA) 
Adalimumab
40 mg/2 wk 67 0 _ _ _ _
+MTX 69 4 _ _ _ _
20 mg/2 wk 73 1 _ _ _ _
+MTX 209 5 2 32 1 0
80 mg/2 wk 62 2 NA NA NA 0 2 0 0
+MTX
Total
Adalimumab
MTX
van de Putte et al. (30) Adalimumab 40 mg/2 wk 113 7 _ _ _ _ _ 1
2 0  m g / 2  w k 1 0 64_ _ _ _ _ 0
20 mg/wk 112 3 _ _ _ _ _ 0
40 mg/wk 103 3 0
Total 434 17 429 53 10 46 4 3
Adalimumab 110 2 105 16 NA 0 1 1 1
Placebo
Furst et al. (31) (STAR) Adalimumab 40 mg/2 wk 318 9 275 17 166 4 62 1 1
DMARD 318 8 275 22 157 6 37 0 1
Keystone y cols. (32) Adalimumab 40 mg/2 wk 207 26 _ _ _ 11 _ _ 2
+MTX* 212 16 _ _ _ 5 _ _ 1
20 mg/wk 419 42 391 97 269 16 101 4 3
+MTX 200 13 181 37 111 1 48 0 0
Total
Adalimumab
MTX
Breedveld et al. (33) (PREMIER) 
Adalimumab
40 mg/2 wk 268 32 _ 9 2 1
+MTX* 274 26 _ 3 4 4
40 mg/2 wk 542 58 524 12 6 5
Total 257 19 245 NA NA 7 NA 4 1
Adalimumab
MTX
NA: not available
* Overall data provided although specific data per arm not provided
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(RA). We have considered these drugs both individually
and as a specific therapeutic group. We have evaluated
their efficacy as monotherapy and in combination with
MTX. In addition, the efficacies of different doses and the
safety of these drugs were explored.
Our search of the literature on the efficacy of anti-TNFα
drugs in RA identified thirteen clinical trials fulfilling the
required criteria for inclusion in the systematic review and
metaanalysis. All thirteen were randomised-controlled tri-
als with a minimal follow-up time of 6 months and used
comparable standardised parameters of efficacy. Although
the general quality of the trials was high, some difficulties
became apparent during the review. The number of trials
fulfilling the required criteria was small. Furthermore,
there were several sources of clinically relevant heteroge-
neity: different control treatments were used, populations
were not homogeneous, follow-up times differed among
trials and the doses administered varied widely (Table 1).
Also, the funnel plot asymmetry might indicate publica-
tion bias or other types of problems.
In our study, combined analysis of the results from all tri-
als using the recommended doses led us to conclude that
anti-TNFα drugs (considered as a therapeutic group) show
an effect significantly superior to that of control treat-
ments. However, the heterogeneity was very high, calling
for subgroups and more homogeneous comparisons. We
only evaluated those trials for which relevant homogene-
ous comparisons were possible, and a substantial reduc-
tion in heterogeneity was apparent when we focused on
these groups (Table 4). Comparison of the three anti-
TNFα drug plus MTX with MTX alone in patients with
insufficient responses to MTX showed no significant het-
erogeneity of effects, yet despite the absence of head to
head comparisons we found no evidence whatsoever that
the relative effects of individual drugs are different.
Etanercept seemed superior to adalimumab when both
drugs were compared to placebo. However, the response
observed in the control group of the adalimumab study
was substantially higher than that of the etanercept refer-
ence group, which casts doubts on the actual comparabil-
ity of the results and makes it difficult to draw definitive
conclusions until the drugs have been compared directly
in well designed, head to head randomised trials. Anti-
TNFα drug plus MTX had a greater effect than MTX alone
in patients with no previous resistance to MTX, but the
magnitude of this effect was markedly lower than that
obtained in patients with previously inadequate
responses to MTX. Trials that assessed this specific efficacy
issue recruited patients with short-lasting, less severe dis-
ease showing high responses to both experimental and
control treatments, thus explaining the lower relative and
absolute efficacy estimates (Table 4). In fact, the effects
achieved with etanercept and adalimumab in these
patients were equivalent to those obtained using MTX for
the first time.
When the potential influence on efficacy of doses admin-
istered was evaluated, both higher and lower doses than
Adverse event withdrawn in patients with all doses of anti-TNFα drugs Figure 9
Adverse event withdrawn in patients with all doses of anti-TNFα drugs.
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Adalimumab  Weinblatt et al, 2003 (29)  0.74  0.15 3.73 5 / 209 2 / 62
Adalimumab  van de Putte et al, 2004 (30)  2.15  0.51 9.19 17 / 434 2 / 110
Adalimumab  Furst et al, 2003 (31)  1.13  0.44 2.88 9 / 318 8 / 318
Adalimumab  Keystone et al, 2004 (32)  1.54  0.85 2.81 42 / 419 13 / 200
Adalimumab  Breedveld et al, 2006 (33)  1.45  0.88 2.38 58 / 542 19 / 257
Adalimumab  1.42  1.01 1.99
Etanercept  Moreland et al, 1999 (24)  1.21  0.32 4.56 7 / 154 3 / 80
Etanercept  Weinblatt et al, 1999 (25)  1.02  0.10 10.77 2 / 59 1 / 30
Etanercept  Bathon et al, 2000 (26)  0.50  0.29 0.87 23 / 415 24 / 217
Etanercept  van der Heijde et al, 2006 (28)  0.76  0.54 1.06 71 / 454 47 / 228
Etanercept  0.70  0.53 0.92
Infliximab  Lipsky et al, 2000 (19)  0.96  0.43 2.14 26 / 340 7 / 88
Infliximab  St Clair et al, 2004 (20)  3.04  1.54 6.01 69 / 751 9 / 298
Infliximab  Quinn et al, 2005 (22)  3.00  0.14 65.90 1 / 10 0 / 10
Infliximab  Westhovens et al, 2006 (23)  2.39  1.13 5.07 38 / 721 8 / 363
Infliximab  2.04  1.34 3.12
Overall  1.25  0.65 2.39
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are currently recommended seemed to elicit similar
effects, except for the effect of lower doses on ACR70.
However, comparisons in this last case are based on a
small number of patients.
In the light of these findings it seems sensible to advise
that current treatment of moderate and severe RA should
be started with MTX. Anti-TNFα drugs should be restricted
to patients who do not respond sufficiently to DMARD
combinations until experimental evidence demonstrates
that the new biological drugs have greater efficacy in ear-
lier stages of RA. It might also be potentially useful to start
the indicated treatment with a low dose and then increase
it as a function of the magnitude of the response. An alter-
native option might be to start with the current recom-
mended doses and try to decrease them after a significant
stable effect is reached, in order to minimise adverse
effects. This issue encompasses important clinical and
Table 6: Adverse events in patients being treated with anti-TNFα drugs versus control
ADVERSE EVENTS (anti TNFα 
vs. control) (references)
Anti-TNFα Anti-TNFα Adverse 
events/total
Controls Adverse 
events/total
RR (95%CI) NNH(95%CI) Q I2 %
Withdrawn adverse event Adalimumab 131/1922 44/947 1.4(1.0–2.0) 47(26–251) 1.2 0
(4826 vs. 2261) Etanercept 103/1082 75/555 0.7(0.5–0.9) -26(-143 a -14) 2.4 0
** 
(19,20,22,23,24,25,26,28,29,30,
31,32,33)
Infliximab 134/1822 24/759 2.0(1.3–3.1) 24(17–41) 4.9 0
Total 368/4826 143/2261 1.3(0.7–2.4) NS 29.3* 59
Total adverse events (3228 vs. 
1564) (19,23,28,30,31,32,33)
Adalimumab 1619/1713 806/885 1.1(0.9–1.1) NS 1.9 0
(3228 vs. 1564) Etanercept 379/454 185/228 1.0(0.9–1.1) NS 0 0
(19,23,28,30,31,32,33) Infliximab 835/1061 322/45 1.0(0.9–1.0) NS 1.6 39
Total 2833/3228 1313/1564 1.0(1.0–1.5) 27(17–59) 2.9 0
Serious adverse events Adalimumab 167/1171 75/628 1.0(0.7–1.4) NS 2.6 25
(3235 vs. 1615) Etanercept 64/454 37/228 0.9(0.5–1.6) NS 0 0
(19,20,22,23,28,30,31,32) Infliximab 217/1610 77/759 1.4(1.0–2.0) 31(17–167) 6.2 52
Total 448/3235 189/1615 1.1(0.8–1.6) NS 14.3* 51
Infections Adalimumab 435/737 268/518 1.1(0.9–1.2) NS 0.7 0
(2341 vs. 1162) Etanercept 315/513 166/258 1.0(0.9–1.0) NS 0.9 0
(19,20,25,28,31,32,33) Infliximab 658/1091 194/386 1.2(1.1–1.3) 10(7–24) 0.03 0
Total 1408/2341 628/1162 1.9(0.9–1.2) NS 8.6 41
Serious infections Adalimumab 44/1922 14/947 1.2(0.6–2.8) NS 5.8 31
(4188 vs.1937) Etanercept 47/454 25/28 0.9(0.4–2.3) NS 0 0
(19,20,22,23,24,25,28,29,30,31,
32,33)
Infliximab 90/1812 19/726 1.8(0.9–3.4) NS 2.7 26
Total 181/4188 58/1937 1.4(0.8–2.2) NS 11.8 32
Infusión reactions
(761 vs. 308)
(20,22)
Infliximab 136/761 20/308 2.7(1.7–4.2) 9(7–14) 0.005 0
Injection-site reactions Adalimumab 241/1380 88/690 1.7(1.0–3.0) 22(13–67) 12.6* 72
(2454 vs. 1245) Etanercept 303/1074 32/555 5.1(2.9–8.8) 5(4–6) 2.3 0
(24,25,26,28,29,30,31,32) Total 544/2454 120/1245 3.0(1.0–8.6) 8(7–10) 51.8* 86
Malignancies Adalimumab 16/1922 5/947 1.1(0.4–2.7) NS 1.6 0
(4826 vs. 2261) Etanercept 15/1082 4/555 1.9(0.6–5.7) NS 0.3 0
(19,20,22,23,24,25,26,28,29,30,
31,32,33)
Infliximab 13/1822 1/759 2.6(0.6–11.6) NS 1.1 0
Total 44/4826 10/2261 1.5(0.8–3.0) NS 3.3 0
Mortality Adalimumab 10/1922 3/947 1.3(0.4–4.7) NS 2.0 0
(4826 vs. 2261) Etanercept 4/1082 1/555 1.5(0.2–9.5) NS 0.2 0
(19,20,22,23,24,25,26,28,29,30,
31,32,33)
Infliximab 9/1822 5/759 0.5(0.2–1.4) NS 0.4 0
Total 23/4826 9/2261 0.8(0.3–2.1) NS 4.4 0
RR (95%CI): relative risk (95% confidence limits)
NNH: number needed to harm
Q: Cochrane's Q
I2: percentage of variability in study results attributable to between-study differences
* statistical heterogeneity
NS: non-significant results
** this figure include 208 patients of the Bathon trial not included in efficacy studies as efficacy date were not reportedBMC Musculoskeletal Disorders 2008, 9:52 http://www.biomedcentral.com/1471-2474/9/52
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economic implications probably meriting further
research.
For a correct interpretation of our results, the fact that our
analyses were based on the ACR response should be taken
into account. In recent years, another multidimensional
index, the DAS index, has been increasingly used [65].
However, it was not used in any of the trials included in
the current review. ACR20, 50 and 70 responses are well-
known validated response criteria and they were available
in all these anti-TNFα studies, enabling us to conduct a
combined analysis and statistical evaluation of the results.
Another important subject in the evaluation of the
response of RA to anti-TNFα drugs is the quantification of
radiological damage (inhibition of progression of struc-
tural joint damage). The modified Sharp score was ana-
lysed in six trials providing 12-month results and showing
the ability of infliximab, etanercept and adalimumab to
inhibit the progression of structural joint damage in RA
[19,20,26,28,32,33]. Nevertheless, several factors deterred
us from using this score as an outcome variable: since it is
not normally distributed, the way this index was summa-
rised and displayed in the identified trials did not permit
statistical pooling of the results. Moreover the clinical
implications of this radiological finding are not yet well
understood.
Safety issues are also of central concern. Although we
focused solely on published results from well-designed
randomised controlled trials, our review shows that
patients receiving anti-TNFα drugs are more prone to
experience adverse events. Although some of the relative
safety estimates are statistically significant, their magni-
tude is rather small and their clinical relevance should be
also addressed. Patients on infliximab and adalimumab
withdrew from the trial because of adverse events more
frequently than patients on etanercept. Treatment with
infliximab is associated with higher frequencies of serious
adverse events and infections. If high doses are adminis-
tered, there is also an increased likelihood of severe infec-
tions. All in all, the safety/efficacy relationship as
estimated by the NNH/NNT ratio appears to be favoura-
ble.
Two metaanalysis have been performed previously
[66,67] focusing the problem, although none has been
published. Both showed a greater efficacy of etanercept
against infliximab. A comprehensive technical report
addressing these issues, including an economic evalua-
tion, has recently been published by Chen et al. [68].
Although the deadline for inclusion of studies was Febru-
ary 2005, that article pooled information from 29 studies
as its inclusion criteria were much broader: it included
studies of shorter duration [46,43,46-48,44], studies
using other than the recommended routes of administra-
tion [49,51,52], studies in which no arm received recom-
mended doses [62] and a trial in which efficacy was not
measured using ACR criteria [58]. It also included unpub-
lished studies. Despite this less restrictive approach, the
Chen et al. paper likewise confirms the efficacy of all three
marketed anti-TNFα drugs at recommended doses, espe-
cially when administered to patients with previous resist-
ance to MTX.
A metaanalysis recently published by Bongartz et al. [7]
focused on safety matters regarding infliximab and adali-
mumab. The risk of malignancies and infections was
increased when higher doses were administered. There
have been some controversies surrounding its conclu-
sions, involving the accuracy of clinical trials with short
follow-up as a means of detecting severe adverse events
[69]. With respect to severe infections, our metaanalysis,
although it detected a higher frequency in the anti-TNFα
arms, showed no significant difference. We pooled safety
data from the three available treatments whereas Bongartz
et al. [7] only analysed infliximab and adalimumab using
a fixed effects pooling method. If we restrict our analysis
to infliximab and adalimumab and use a fixed effects
model, we also find a significantly higher frequency of
severe infections (p = 0.047) with an NNH of 61 (41–
126). Therefore, it is likely that the use of both drugs,
especially in higher than recommended doses, may
increase the risk of severe infections. This risk has not so
far been shown for etanercept, but as far as we are aware
no study with higher than recommended doses has been
published. Our results regarding the incidence of malig-
nancies do not agree with those of Bongartz et al. [7], but
they also include malignancies developed at a later stage
when the trials are no longer underway.
Recently, two systematic reviews with meta-analysis have
been published addressing the role of anti-TNFα drugs as
added to MTX vs. MTX alone [70,71]. Both articles select
a very limited number of trials, and share an important
design limitation, namely, they compare clinical trials
that recruit both MTX-naïve patients and MTX-resistant
patients, which, from our standpoint leads to their results
facing validity problems.
There are limitations to our study that are also shared by
other published metaanalyses [7,68] and deserve further
comment. The number of published studies is scarce,
there is significant heterogeneity in some relevant aspects
(patient clinical profiles, comparisons undertaken and
lengths of follow-up) and information on safety parame-
ters varies widely among trials. We have attempted to deal
with these limitations in the original research by design-
ing and applying rather stringent selection criteria so that
our results are based on solid coherent evidence. This rein-
forcement of internal validity might have been at theBMC Musculoskeletal Disorders 2008, 9:52 http://www.biomedcentral.com/1471-2474/9/52
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expense of some loss of generalizability, yet the quality of
information excluded is at least controversial. We have
provided these pooled NNTs as a kind of effect estimate
for average risk patients. In an attempt to minimise the
presence of factors known to influence risks and therefore
NNTs, we have selected rather homogeneous studies in
terms of minimum follow-up, diagnostic criteria and have
further made subgroup analyses accounting for several
important clinical characteristics. We have performed an
extensive and detailed analysis of available efficacy and
safety data.
Conclusion
It may be concluded that the three marketed anti-TNFα
drugs are more effective than the corresponding control
treatments (MTX or placebo) in RA patients, with an NNT
of 5 for ACR20 and ACR50 and of 7 for ACR70 at cur-
rently recommended doses (Table 3). High heterogeneity
among trials is apparent in key design aspects and is
reflected in the results of the combined analysis of all tri-
als, calling for more in-depth assessment of more homo-
geneous subgroups. When this task is addressed, patients
with previously inadequate responses to MTX show simi-
lar positive responses when any of the anti-TNFα drugs
are added to their treatment regimes. However, when anti-
TNFα drug plus MTX is compared with MTX alone in
patients with no previous resistance to MTX, the relative
efficacy of the combined regime is much lower. Etanercept
and adalimumab are superior to the placebo but their
effect in monotherapy is similar to that obtained with
MTX. Therefore, we advise against starting treatment with
anti-TNFα drugs until a lack of adequate response to MTX
is clearly documented. Increasing doses lead to no
increase in efficacy (Table 3). Analysis of the effect of low
anti-TNFα doses suggests that patients treated with etaner-
cept or adalimumab might obtain clinically substantial
benefits with doses lower than those currently recom-
mended if indicated on the basis of safety or other
grounds.
Overall, patients on anti-TNFα drugs experience adverse
events more frequently and those using infliximab and
adalimumab have higher withdrawal rates. Infliximab use
is associated with a higher likelihood of severe adverse
events including severe infections. Interestingly, though,
patients using etanercept seem to do so with lower fre-
quency, although this finding might be due to the limita-
tion of the range of doses used to those recommended by
the manufacturer. We found no significant difference in
the development of malignancies during the follow-up
times in the studies. The safety/efficacy relationship is
favourable, especially if recommended doses are used.
The safety profile of etanercept might be apparently supe-
rior because the other drugs were tested over a wider range
of doses, including higher than recommended ones.
Although more research is warranted, especially well-
powered head to head randomised comparisons of anti-
TNFα drugs, our study helps to clarify some frequently
encountered questions in the clinical care of RA patients.
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